ISPOR’s 21st Annual International Meeting is scheduled for 20-25th May 2016 in Washington DC. Several members of the OHE team will be attending and disseminating important research.

ISPOR’s 21st Annual International Meeting will be held 20-25th May 2016 in Washington DC. Several members of the OHE team will be attending and disseminating important research. We would welcome the opportunity to meet with you to discuss our research; individual contact details can be found through our Meet the Team webpage.

You will also find members of the OHE team presenting at the following sessions:

Short course: Risk Sharing / Performance-Based Arrangements for Drugs and Other Medical Products

OHE Authors: Adrian Towse

Time and date: Saturday 21st May, 8:00am

Summary: There is significant and growing interest among both the payers and producers of medical products for arrangements that involve a “pay-for-performance” or “risk-sharing” element. These payment schemes involve a plan by which the performance of the product is tracked in a defined patient population over a specified period of time and the level of reimbursement is tied by formula to the outcomes achieved. Although these agreements have an intrinsic appeal, there can be substantial barriers to their implementation. Issues surrounding theory and practice, including incentives and barriers, will be analysed along with several examples of performance-based schemes from Europe, the United States, and Australia.

Short course: Using Multi-Criteria Decision Analysis in Health Care Decision Making: Approaches & Applications

OHE Authors: Martina Garau and Nancy Devlin.  

Time and date: Sunday 22nd May, 1:00pm.

Summary: The aims of the course are:

• To outline the steps involved in implementing multi-criteria decision analysis (MCDA)
• To explain some of the methodological choices and practical issues when implementing these steps
• To demonstrate how MCDA is being used for health technology assessment (HTA), the challenges and the opportunities this poses, and possible solutions to these challenges.

Research Podium Presentation: Health Care Expenditure Series: Multi-Indication Pricing: Pros, Cons and its Applicability to the UK

OHE Authors: Jorge Mestre-Ferrandiz  and Adrian Towse

Time and date: Monday 23rd May, 3:45pm.

Summary: Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. This presentation will explore the feasibility of implementing MIP in the UK.

Workshop: Risk-Sharing Agreements for Manufacturers and Commercial Payers in the United States: How Can Theory Help Practice?

OHE Authors: Adrian Towse

Time and date: Monday 23rd May, 5:00pm – 6:00pm.

Summary: Previous research has documented the limited use of risk-sharing agreements (RSAs) in the U.S. commercial sector for both medicines and devices. Research has also identified numerous practical barriers, including the costs of reaching an agreement and the lack of adequate data infrastructure. From a theoretical perspective, these agreements attempt to address the key uncertainties by (1) collecting real-world data post-launch, and (2) sharing risk by adjusting post-launch reimbursement. This problem has been characterized from a variety of theoretical perspectives–from value of information theory to real option theory to Bayes theorem. This workshop explores the utility of these approaches to help parties to the agreement construct an arrangement appropriate to the source of the uncertainty and their risk preferences. 

Issue Panel: Multi-Indication Pricing: Do We Want It? Can We Operationalize It?

OHE’s Adrian Towse will moderate this issue panel.

Time and date: Tuesday 24th May, 11:00am – 12:00pm.

Summary: Economic assessment will often describe different incremental health gains for different uses of a drug. This may be in different indications for the same drug or in different groups of patients (e.g. high risk / low risk) for the same indication. However, most health care reimbursement models use a single reimbursement price regardless across all indications. Multi-indication drug pricing represents a potential shift in drug reimbursement practice and has been debated in policy forums in both Europe and the US. Adrian Towse will moderate and briefly present a European perspective including opinions from an OHE supported stakeholder forum. Bill Dreitlein will provide US perspective including opinions from an ICER supported stakeholder forum. Ansgar Hebborn will provide a manufacturer’s point of view. Sean Karbowicz will provide a US payer’s perspective.

Poster: Value of Transferability and Efficiency in HTA

OHE Authors: Bernarda Zamora, Grace Marsden and Adrian Towse

Time and date: Monday 23rd May, 3:45pm – 7:45pm. Poster Author Discussion Hour: 6:45pm – 7:45pm

Summary: Existing literature on transferability advises that multinational trials should report country-specific cost-effectiveness results, yet typically these country specific results are only used to assess the between-location variability. 

We use value of information (VOI) analysis (assuming a normal distribution) to show that country specific results can be used to calculate the value of transferability (transfer from the wide trial to the country of interest) in terms of the Expected Value of Sample Information (EVSI).

Poster: The Distribution of the EQ-5D-5L Index in Patients Populations

OHE Authors: Yan Feng, Nancy Devlin and Bernarda Zamora.

Time and date: Monday 23rd May, 3:45pm – 7:45pm. Poster Author Discussion Hour: 6:45pm – 7:45pm

Summary: The distribution of the EQ-5D-3L index in patient populations often shows two distinct groups, arising both from the distribution of ill health and how the EQ-5D-3L index is constructed. This study aims to explore (a) whether or not the EQ-5D-5L index distribution also demonstrates clustering; (b) the extent to which clustering of EQ-5D-5L profile data is a driver of any observed clustering of the EQ-5D-5L index; and the extent to which clusters are a product of the value sets used to estimate the EQ-5D-5L index; and (c) to highlight the implications of our results for statistical analysis of EQ-5D-5L index data.

Poster: An Exploration of the Cultural Differences between the General Populations of Europe and Japan in Self-Reporting and Valuation of Pain

OHE Authors: Yan Feng and Nancy Devlin

Time and date: Tuesday 24th May, 3:45pm – 7:45pm. Poster Author Discussion Hour: 6:45pm – 7:45pm

Summary: This research investigates whether there are differences in the self-reporting and valuation of pain/discomfort between three countries (England/UK, Japan and Spain) on EQ-5D. Existing data sets were used to explore differences in responses to the EQ-5D descriptive system between Japan (3L and 5L), the UK (3L), England (5L) and Spain (5L), particularly on the dimension of pain/discomfort.

Poster: Health Technology Assessment of Complementary Diagnostics: Issues, Options, and Opportunities

OHE Authors: Jorge Mestre-Ferrandiz and Bernarda Zamora

Time and date: Wednesday 25th May, 8:30am – 1:30pm. Poster Author Discussion Hour: 12:30pm – 1:30pm

Summary: The poster is based on a White Paper which looks at the new concept of “complementary diagnostics”, defining tests using biomarkers for the purposes of risk assessment, diagnosis, prognosis, monitoring, and guiding therapeutic decisions. The White Paper presents a more comprehensive framework for considering the value contribution of complementary diagnostics. Going beyond the usual focus on health gain and cost savings, the framework highlights the value to the patient of having greater certainty of treatment benefit. The Paper also identifies several other sources of value related to information, including real option value, the value of hope, insurance value and scientific spillovers.

Poster: Data Governance for Real-World Evidence: Cross-Country Differences and Recommendations for a Governance Framework

OHE Authors: Jorge Mestre-Ferrandiz and Amanda Cole

Time and date: Wednesday 25th May, 8:30am – 1:30pm. Poster Author Discussion Hour: 12:30pm – 1:30pm

Summary: Real-world data (RWD) becomes real-world evidence (RWE) – what is really of value to stakeholders – after a series of activities which facilitate the transformation of raw data into analysis and results. Appropriate and facilitative governance arrangements for RWE are imperative to facilitate evidence collection that meets the demands of regulators and HTA bodies, and to make the most of health care information and the role it can play in improving patient care.

Poster: Does Society Wish to Place Greater Weight on a Unit of Health Gain for End-of-Life Patients than on that for Other Types of Patients?

OHE Authors: Koonal Shah

Time and date: Wednesday 25th May, 8:30am – 1:30pm. Poster Author Discussion Hour: 12:30pm – 1:30pm

Summary: This poster provides a review of the published literature on society’s preferences regarding the prioritisation of end of life treatments. Seventeen empirical studies are included in the review. Preliminary results were featured in a previous OHE blog.

Poster: Important Aspects of (Full) Health Not Captured by EQ-5D

OHE Authors: Koonal Shah

Time and date: Wednesday 25th May, 8:30am – 1:30pm. Poster Author Discussion Hour: 12:30pm – 1:30pm

Summary: This poster presents the methods and findings of a study seeking to identify important aspects of health that are not captured by the five EQ-5D dimensions. The study draws on the views of 456 members of the UK general public.

For further information on any of these presentations please contact the OHE authors via our Meet the Team webpage.